Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03073486 · ClinicalTrials.gov registry record · Phase 3
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
A Phase 3 study of Acne Vulgaris, sponsored by Dermira.
- Completed
- Registry status
- Phase 3
- Development phase
- 744
- Enrollment target
- 20
- Study locations
NCT03073486 is a Phase 3 study of Acne Vulgaris that has completed, run by Dermira. The registered enrollment target is 744 participants, above the 264-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (182% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT03073486, a Phase 3 study of Acne Vulgaris, has completed, sponsored by Dermira.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 744 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objectives of this study are to assess the safety and efficacy of Olumacostat Glasaretil Gel compared to vehicle in patients with acne vulgaris
Conditions Studied
Interventions
- DRUG Olumacostat Glasaretil Gel, 5.0%
- OTHER Olumacostat Glasaretil Gel, Vehicle
Study Locations (20)
Florida
- Center for Clincial and Cosmetic Research - Aventura
- Florida Academic Centers Research & Education - Coral Gables
- Aby's New GEneration Research Inc. - Hialeah
- Health Awareness, Inc. - Jupiter
- Floridian Research Institute - Miami
- Pioneer Clinical Research - Pembroke Pines
- Radiant Research, Inc. - Pinellas Park
- MOORE Clinical Research, Inc - Tampa
- Visions Clinical Research - Wellington
California
- Center for Dermatology Clinical Research, Inc. - Fremont
- Advanced Skincare Surgery & MedCenter - Fullerton
- Northern California Research - Sacramento
- TCR Medical Corporation - San Diego
- Radiant Research, Inc. - Santa Rosa
Arkansas
- Dermatology Trial Associates - Bryant
- Northwest Arkansas Clinical Trials Center - Rogers
Alabama
- Avant Research Associates, LLC - Guntersville
Arizona
- Advanced Research Associates - Glendale
Colorado
- Alpine Clinical Research Center - Boulder
Georgia
- Marietta Dermatology Clinical Research, Inc. - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 744 participants |
| Start Date | 2017-02-06 |
| Est. Completion | 2017-12-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03073486
The ClinicalTrials.gov registry entry for NCT03073486 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 744 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 264-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (182% higher). The listed sponsor is Dermira, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Olumacostat Glasaretil Gel, 5.0% is the first listed.
NCT03073486 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03073486 about?
NCT03073486 is a clinical study titled "A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris". The objectives of this study are to assess the safety and efficacy of Olumacostat Glasaretil Gel compared to vehicle in patients with acne vulgaris
What is the current status of trial NCT03073486?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 744 participants. The study started on 2017-02-06. Estimated completion is 2017-12-21.
What conditions does trial NCT03073486 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT03073486?
The interventions under investigation include: Olumacostat Glasaretil Gel, 5.0% (DRUG), Olumacostat Glasaretil Gel, Vehicle (OTHER).
Who is sponsoring clinical trial NCT03073486?
This trial is sponsored by Dermira, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03073486 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
COMPLETED · Phase 3
-
A Study of S6G5T3 in the Treatment of Acne Vulgaris
COMPLETED · Phase 3
-
P3 Long Term Safety Study of Once Daily SB204 in Acne
COMPLETED · Phase 3
-
Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne
COMPLETED · Phase 3
-
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
COMPLETED · Phase 3
-
A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.